What FDA Looks for During a Radiopharmaceutical GMP Audit under 21 CFR Part 212

radiopharmaceutical-gmp-audit-21-cfr-212

Radiopharmaceutical manufacturing operates under a unique set of regulatory expectations. Unlike traditional pharmaceutical products, these drugs involve short half-lives, specialized containment, and the dual requirements of both cGMP and radiation safety. FDA inspects these facilities primarily under 21 CFR Part 212, and the focus areas differ significantly from a standard 21 CFR 210/211 inspection.

With nearly 30 years of experience in GxP and extensive work supporting radiopharmaceutical operations, I have seen how well-prepared sites consistently perform better during inspections. Below are the key areas FDA typically examines during a radiopharmaceutical GMP audit.

Key Areas of Focus in a 21 CFR 212 Audit

1. Hot Cell and Isolator Qualification Inspectors closely review installation, operational, and performance qualification (IQ/OQ/PQ) records for hot cells, isolators, and related equipment. They look for clear acceptance criteria, evidence of ongoing monitoring, and proper change control when modifications occur.

2. Aseptic Processing Controls Because many radiopharmaceuticals are sterile injectables produced under time pressure, aseptic technique, media fills, and environmental monitoring data receive careful scrutiny. FDA expects robust controls even when production batches are small or frequent.

3. Radiation Safety (ALARA) Integration with cGMP One of the most distinctive aspects of radiopharma audits is how radiation safety practices are integrated into the quality system. Inspectors evaluate whether ALARA principles are documented, followed, and aligned with manufacturing procedures rather than treated as a separate program.

4. Batch Records and Data Integrity Short half-life products require fast, accurate documentation. FDA examines whether batch records are complete, contemporaneous, and support full traceability—especially for critical steps that cannot be repeated.

5. Environmental Monitoring and Facility Controls Trends in viable and non-viable monitoring, pressure cascades, and cleanroom classification maintenance are reviewed to confirm the facility remains in a state of control.

6. Supplier Qualification Isotopes, precursors, and sterile components must come from qualified suppliers. Inspectors often request evidence of risk-based supplier evaluation and ongoing oversight.

Common Gaps That Lead to Observations

In my experience, the most frequent weaknesses include:

• Incomplete or outdated hot cell qualification packages

• Insufficient linkage between radiation safety and GMP procedures

• Gaps in environmental monitoring trending and response

• Weak documentation practices around rapid production cycles

• Limited evidence of effective CAPA for recurring issues

  
  

How to Strengthen Inspection Readiness

Sites that perform well usually maintain:

• Clear, current qualification status for all critical equipment

• Strong collaboration between Quality, Production, and Radiation Safety

• Practical, well-trained personnel who understand both GMP and radiation requirements

• Regular internal audits focused specifically on 21 CFR 212 expectations

Need Support with Radiopharmaceutical GMP Audits?

I specialize in radiopharmaceutical compliance and 21 CFR Part 212 audits. Whether you need a full facility audit, a mock FDA inspection, gap assessment, or targeted remediation support, I provide practical, senior-level guidance—fully remote or on-site.

Learn more about our radiopharmaceutical services: https://www.gxpauditconsult.com/services/radiopharma

Contact us to schedule a consultation:

https://www.gxpauditconsult.com/contact-us